Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability (PHATHOM)

This Phase I study evaluates safety and tolerability of psilocybin administered as either a single 25 mg dose or a split 12.5 mg + 12.5 mg dose (second dose 2 hours later) in individuals at least 12 months post-ischemic or haemorrhagic stroke.

Secondary objectives include exploratory assessment of psilocybin's potential to enhance motor recovery after stroke, informed by preclinical data suggesting psychedelics may reopen critical periods for learning.